Binetrakin

Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, offering potential for improved breathing and fewer exacerbations.

Dupixent, a drug by Sanofi and Regeneron, has received FDA approval for treating COPD, becoming the first biologic therapy for the condition. The drug targets type 2 inflammation driven by eosinophils, showing significant reductions in COPD exacerbations in Phase 3 trials. Dupixent has previously been approved for dermatitis and asthma, contributing to €10.7 billion in sales in 2023.

Cell lines, reagents, and in vitro studies were conducted to assess cytotoxicity and proliferation of cells treated with Minnelide. Protein modeling and ligand preparation were performed using specific software and force fields. Mouse tumor implantation and flow cytometry were used to analyze immune profiling and immune cell markers. RT-PCR and Western Blot analysis were employed to measure gene expression and protein levels, respectively. Statistical analysis was conducted using GraphPad Prism.

FDA approves Dupixent as add-on treatment for adults with uncontrolled COPD, marking the first biologic therapy for this condition. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation pathways and has shown efficacy in reducing COPD exacerbations and improving lung function in phase 3 trials. The drug also has other approved uses and is being studied for bullous pemphigoid.

Dupixent approved by FDA as the first biologic medicine for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improvements in lung function, and health-related quality of life.

FDA approves Sanofi/Regeneron’s Dupixent as first biologic for uncontrolled COPD, following EMA approval. Dupixent targets IL4 and IL13 pathways, reducing exacerbations and improving lung function. GlobalData forecasts $6.57 billion in sales by 2033.

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with inadequately controlled COPD with an eosinophilic phenotype. Dupilumab, an IL-4 and IL-13 pathway inhibitor, demonstrated a reduction in annual exacerbations in phase III trials BOREAS and NOTUS. It also improved quality of life and lung function. Common adverse events included viral infection, headache, and nasopharyngitis.

Dupixent approved by FDA as add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype, based on Phase 3 trials showing significant reduction in exacerbations, improvements in lung function and quality of life.

The FDA approves Dupixent as the first biologic for COPD patients with an eosinophilic phenotype, based on phase 3 studies showing reduced exacerbations and improved lung function.